[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravascular-imaging-and-microvascular-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravascular-imaging-and-microvascular-obstruction":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652303","multimodal-biomarkers-in-coronary-artery-disease-pathogenesis-the-oxford-acute-myocardial-infarction-study-oxami-study-100652303",false,"NCT07772570","Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)","OXAMI","Inclusion Criteria:\n\n* Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND\u002FOR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.\n\nExclusion Criteria:\n\n* Patients in whom safety or clinical concerns preclude participation.\n* Anaemia (Hb \\\u003C9).\n* Pregnant or breast feeding females.\n\nAdditional exclusion criteria for patients undergoing MRI\n\n* claustrophobia which limits \u002F prevents participants from remaining in MRI scanner.\n* patients who cannot lie flat on the scan table.\n* patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.\n* patients with known allergy to medium of contrast (gadolinium)\n\nAdditional exclusion criteria for patients undergoing coronary CT angiography\n\n* patients with a known allergy to iodinated contrast media\n* eGFR\\\u003C 30 ml\u002Fmin (stage 3-5 renal disease)",true,"ALL","18 Years","90 Years",{"count":21,"type":22},2000,"ESTIMATED","20 Years","OBSERVATIONAL","Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.\n\nAlthough much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.\n\nThe Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. We will study both the disease within the coronary arteries (the \"upstream\" problem) and its effects on the heart muscle (the \"downstream\" damage). By examining these together, we hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.\n\nPatients undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, we may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing us to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.\n\nWe will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). We may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.\n\nNon-invasive heart scans may include cardiovascular magnetic resonance (CMR\u002FMRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for patients who arrive at hospital several hours after their heart attack began.\n\nOther measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.\n\nBlood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.\n\nWith additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.\n\nBy combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, OxAMI aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.\n\nUltimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.",[27,28,29,30,31,32,33,34,35],"Myocardial Injury","Atherosclerosis Cardiovascular Disease","Cardiac Imaging Techniques","Genetics","Thrombus","Trained Immunity","Biomarker Discovery","Coronary Physiology","Intravascular Imaging and Microvascular Obstruction","RECRUITING","2026-08-14",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":40},"2012-05",{"date":44,"type":22},"2046-12",{"name":46,"class":47},"University of Oxford","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100527948","study-on-the-improvement-of-myocardial-microcirculation-after-acute-anterior-myocardial-infarction-100527948","NCT06154395","Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction","A Comparative Study of 60 MHz HD-IVUS, OCT, and Conventional Angiography to Guide Reperfusion Therapy for Improving Myocardial Microcirculation Dysfunction After Acute Anterior Myocardial Infarction","Inclusion Criteria:\n\nClinical Inclusion Criteria:\n\n1. Subjects aged ≥18 years;\n2. Initial diagnosis of anterior wall ST-segment elevation myocardial infarction, with symptoms occurring within 6 hours, and undergoing primarypercutaneous coronary intervention (PCI);\n3. Subjects (or legal representatives) who understand the study requirements and treatment procedures and provide signed informed consent.\n\nImaging Inclusion Criteria (Visual Estimation):\n\n1. Target lesion is the culprit lesion, located in the native coronary artery, with a visually estimated reference vessel diameter (RVD) between 2.25 mm and 4.0 mm;\n2. Culprit segment of the infarct-related artery (IRA) is located between the origin of the left anterior descending (LAD) artery and the emergence of the second diagonal branch (D2);\n3. After pre-treatment , the degree of stenosis in the LAD is ≤90%, and TIMI flow is grade 3.\n\nExclusion Criteria:\n\nClinical Exclusion Criteria:\n\n1. History of coronary artery bypass grafting (CABG);\n2. Known history of myocardial infarction or PCI;\n3. Previous thrombolytic therapy before PCI;\n4. Severe liver or kidney dysfunction, severe valvular heart disease, chronic obstructive pulmonary disease, etc.;\n5. Contraindications to magnetic resonance imaging;\n6. Allergy to gadolinium contrast agents and\u002For accompanying medications for devices or procedures (e.g., any component of drug-eluting stents, all P2Y12 inhibitors, or aspirin);\n7. Expected lifespan of the subject less than 12 months;\n8. Pregnant or lactating females;\n9. Other subjects deemed unsuitable for participation in the study by the investigator.\n\nImaging Exclusion Criteria (Visual Estimation):\n\n1. Presence of lesions requiring intervention other than the target lesion at baseline surgery;\n2. No protected left main coronary artery disease (visual estimate of stenosis \\>50%);\n3. Diffuse severe calcification (\\>20 mm) or chronic total occlusion in the major coronary vessels (LCX, RCA);\n4. Severe coronary artery tortuosity (\\>45°) or calcification (\\>270°), or other conditions that may interfere with the use of intravascular imaging.",{"count":57,"type":22},90,"INTERVENTIONAL",[60],"NA","This study is a prospective, single-center, randomized controlled clinical trial. Ninety patients with anterior wall ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset will be screened. Patients with inclusion criteria and without exclusion criteria will be randomized into three groups in a 1:1:1 ratio: OCT-guided group, 60 MHz HD-IVUS-guided group, and angiography-guided group after signing the informed consent form.\n\nBased on the lesion characteristics detected by imaging in each group, coronary revascularization will be performed for the culprit vessels of myocardial infarction. The TIMI myocardial perfusion frame count (TMPFC) values of the culprit vessels will be recorded immediately after PCI, and secondary prevention medications for myocardial infarction will be administered. Three days after the procedure, a 3.0T cardiac magnetic resonance imaging (MRI) with gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) delayed enhancement (LEG) scan will be conducted to assess the microvascular obstruction (MVO) area.\n\nPatients will be followed in the outpatient clinic visit at 1 month (with a window period of XX days) after discharge, and a repeat cardiac MRI will be performed to determine the presence of MVO and the size of the myocardial infarction.",[35],"2024-10-16",{"date":65,"type":40},"2024-10-18",{"date":67,"type":40},"2023-12-20",{"date":69,"type":22},"2025-06-30",{"name":71,"class":47},"Harbin Medical University"]